Get the Stockscreener App
8.28
1.35%
0.14
Sight Sciences Inc stock is traded at $8.28, with a volume of 304.45K.
It is up +1.35% in the last 24 hours and up +64.01% over the past month.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
See More
Previous Close:
$8.14
Open:
$8.1
24h Volume:
304.45K
Relative Volume:
1.48
Market Cap:
$456.13M
Revenue:
$79.55M
Net Income/Loss:
$-37.25M
P/E Ratio:
-11.74
EPS:
-0.7054
Net Cash Flow:
$-25.40M
1W Performance:
+7.14%
1M Performance:
+64.01%
6M Performance:
+54.20%
1Y Performance:
+96.42%
1-Day Range:
$7.89
$8.40
1-Week Range:
$7.6051
$8.60
52-Week Range:
$3.19
$9.2362
Sight Sciences Inc Stock (SGHT) Company Profile
Name
Sight Sciences Inc
Sector
Industry
Phone
(415) 889-0550
Address
4040 CAMPBELL AVE,, MENLO PARK
Compare SGHT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGHT
Sight Sciences Inc
|
8.28 | 448.42M | 79.55M | -37.25M | -25.40M | -0.7054 |
ABT
Abbott Laboratories
|
110.23 | 192.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
332.55 | 130.11B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
90.62 | 116.83B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
51.56 | 75.11B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.86 | 52.80B | 6.30B | 1.07B | 1.09B | 1.8406 |
Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-08-25 | Upgrade | Lake Street | Hold → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Nov-04-24 | Downgrade | Lake Street | Buy → Hold |
| Aug-21-24 | Initiated | Lake Street | Buy |
| Sep-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-12-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-24-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-23 | Upgrade | Stifel | Hold → Buy |
| Oct-04-22 | Initiated | Needham | Hold |
| Jul-26-22 | Initiated | Stifel | Hold |
| Feb-03-22 | Initiated | William Blair | Outperform |
| Jan-07-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Sight Sciences Inc Stock (SGHT) Latest News
Sight Sciences (SGHT) insider plans 48,000-share stock sale after option exercise - Stock Titan
SGHT (SGHT) holder files to sell 2,500 shares after stock vesting - Stock Titan
Sight Sciences (SGHT) Q2 2026 Earnings Call Transcript - AOL.com
SGHT insider Jeremy Hayden files Form 144 for recent and planned stock sales - Stock Titan
Sight Sciences Inc (NASDAQ: SGHT) Share Price, SGHT Stock News, SGHT Share Price & Updates - kalkine.com.au
SGHT (NASDAQ: SGHT) insider Jeremy Hayden plans $165,878 stock sale - Stock Titan
Sight Sciences appoints Kashif Rashid as chief legal officer, Jeremy Hayden to step down By Investing.com - Investing.com Australia
Sight Sciences Names Kashif Rashid as New Chief Legal Officer Amid Leadership Change - Kalkine Media
Sight Sciences names Kashif Rashid chief legal officer, replacing Jeremy Hayden - Bitget
Sight Sciences Appoints New Chief Legal Officer Rashid - TipRanks
Sight Sciences appoints Kashif Rashid as chief legal officer, Jeremy Hayden to step down - Investing.com Nigeria
Form 8K Sight Sciences Inc For: 10 August By Investing.com - Investing.com Nigeria
Sight Sciences(SGHT) Stock Options Chain | Quotes & News - Moomoo
Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance - 富途牛牛
Sight Sciences (NASDAQ:SGHT) Rating Increased to Buy at Wall Street Zen - MarketBeat
A Quick Look at Today's Ratings for Sight Sciences(SGHT.US), With a Forecast Between $8 to $12 - Moomoo
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Sight Sciences (SGHT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), Revolution Medicines (RVMD) and Sight Sciences (SGHT) - The Globe and Mail
UBS Group Forecasts Strong Price Appreciation for Sight Sciences (NASDAQ:SGHT) Stock - MarketBeat
UBS Adjusts Price Target on Sight Sciences to $8 From $7, Maintains Buy Rating - marketscreener.com
Sight Sciences, Inc. Stock 12‑Month Price Target Raised to $8.6, Implies 55% Upside - TradingView
Sight Sciences Q2 Earnings Call Highlights - MarketBeat
Sight Sciences Sees Q2 Revenue Growth, Raises 2026 Guidance - VisionMonday.com
Sight Sciences (NASDAQ:SGHT) Posts Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
Sight Sciences (SGHT) Stock Sees Modest Fair Value Cut As Analysts Revisit Guidance - Yahoo Finance
Earnings call transcript: Sight Sciences raises 2026 outlook on Q2 growth, shares fall - Investing.com Nigeria
Sight Sciences, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Sight Sciences : Reports Second Quarter 2026 Financial Results - marketscreener.com
Sight Sciences wins FDA clearance for Omni Surgical System - MassDevice
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Aetna covers Sight Sciences glaucoma devices for commercial plans By Investing.com - Investing.com South Africa
Sight Sciences Q2 revenue rises 20%, beats estimates - TradingView
Aetna covers Sight Sciences glaucoma devices for commercial plans - Investing.com
Sight Sciences, Inc. Provides Earnings Guidance for the Third Quarter of 2026 - marketscreener.com
Sight Sciences, Inc. Q2 2026: Revenue $23.39M, EPS $(0.08) — 10-Q Summary - TradingView
Sight Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Sight Sciences (NASDAQ: SGHT) lifts 2026 outlook after 20% Q2 growth - Stock Titan
Sight Sciences Reports Second Quarter 2026 Financial Results - The Manila Times
Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems - The Manila Times
BRIEF-Sight Sciences Q2 Revenue USD 23.4 Million Vs. IBES Estimate USD 21.7 Million - TradingView
Sight Sciences publishes investor presentation on interventional glaucoma, dry eye platforms - Bitget
FDA Clears Sight Sciences’ OMNI Ultra Surgical System - Medical Product Outsourcing
FDA clears Sight Sciences’ OMNI Ultra glaucoma device - Investing.com
FDA clears Sight Sciences’ OMNI Ultra glaucoma device By Investing.com - Investing.com India
Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System - The Manila Times
Sight Sciences Announces FDA 510(k) Clearance of OMNI Ultra Surgical System for Primary Open-Angle Glaucoma - Quiver Quantitative
Sight Sciences' FDA-cleared glaucoma system leaves no implant behind - stocktitan.net
Sight Sciences wins FDA 510(k) clearance for OMNI Ultra glaucoma system - Bitget
Earnings To Watch: Sight Sciences Inc (SGHT) Q2 2026 -- GF Value Sees 9% Downside - Yahoo Finance
Sight Sciences, Inc. expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Sight Sciences Inc Stock (SGHT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):